Navigation Links
U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan
Date:9/1/2009

MOUNTAIN VIEW, Calif., Sept. 1 /PRNewswire/ -- The maturity of the U.S. compression therapy market is necessitating the introduction of advanced technologies to break the growth plateau. Manufacturers are using the concept of evidence-based medicine to educate physicians and encourage the adoption of new technologies. Growing health awareness among consumers has spurred the demand for early diagnosis and preventive approaches. This, coupled with the increasing incidence of obesity and chronic wounds, is fuelling the compression therapy market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.medicaldevices.frost.com), U.S. Compression Therapy Market, finds that market earned revenues of over $673.7 million in 2008, and estimates this to reach $1.16 billion in 2015. The study covers market dynamics, revenue forecast analysis, and patient population trends for the static and dynamic compression therapy segments.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Johanna Haynes at johanna.haynes@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

Chronic venous disease (CVD) of the lower extremity affects an estimated 40 percent of the U.S. population, accounting to 4.6 million lost working days every year.

"Compression therapy has evolved to be the mainstay of treatment and management of chronic venous insufficiency and venous ulcers," explains Frost & Sullivan Research Analyst Archana Swathy. "Currently, compression therapy is being aggressively adopted in the prevention of post-operative deep vein thrombosis (DVT)."

As hospitals strive to control costs through early discharges, the demand for home-use therapy products is on the rise. Consumers are displaying a preference for multi-functional, high-quality products that also offer the benefits of reduced treatment time. The current market need is patient-friendly products that suit patient lifestyles and afford better compliance to therapy. The development of mobile compression systems will improve market prospects, as they will cater to consumers who intend to stay active even while undergoing therapy.

Aesthetically pleasing and easy-to-use compression garments will go a long way in enabling patient compliance to treatment. There also exists a pressing need to establish clinical evidence that highlights the advantages of intermittent pneumatic compression (IPC), in comparison with other treatment modalities. This approach would be beneficial in enhancing market penetration of dynamic compression products.

"There is a significant lack of differentiation among compression therapy products currently available in the market," observes Archana. "The need for highly distinctive products should ideally result in manufacturers developing compact portable devices that would significantly enhance the healing process."

The lack of sufficient awareness among healthcare practitioners about the significance of new compression technologies is restraining market progression. Building awareness among physicians and care providers regarding the benefits afforded by dynamic compression therapy, such as cost effectiveness and clinical efficiency, is vital for the growth of innovative technologies.

U.S. Compression Therapy Market is part of the Medical Devices Growth Partnership Service program, which also includes research in the following markets: U.S. Hip Implant Market, U.S. and Western Europe Adhesion Prevention Products Market, U.S. Soft Tissue Repair Markets - Meniscus and Cartilage, Cardiovascular Business Digest - U.S. Heart Valve Market, and U.S. Infusion Pumps Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

                         U.S. Compression Therapy Market
                                       N5D4

    Contact:
    Johanna Haynes
    Corporate Communications - North America
    P: 210.247.3870
    F: 210.348.1003
    E: johanna.haynes@frost.com

    Jake Wengroff
    Corporate Communications - North America
    P: 210. 247.3806
    F: 210.348.1003
    E: jake.wengroff@frost.com

   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Surgery, Sham Equal in Treating Compression Fracture Pain
2. Samplify Systems Announces Next Generation Signal-Compression Technology, Prism 3.0
3. Spinal Decompression Therapy Offers Hope for Back Pain
4. Global Decompression Announces C.O.D. Available on All Used Axiom DRX 9000 Spinal Decompression Systems
5. Compression Stockings Offer Little Benefit After Stroke
6. Samplify Rolls Production Quantities of Its SAM1600 Analog/Digital Converters with Real-Time Data Compression
7. Syndication Inc. Seeks Director of Marketing for Sy-Med Decompression Centers; BOD Considers Adding a Green Energy New Company Subsidiary to its Ranks
8. Samplify Systems Announces Availability of Worlds First 16-channel, 12-bit, 65 Msps A/D Converter With Integrated Real-Time Data Compression
9. New Website Portal Delivers Pre-Qualified Spinal Decompression Patients to Participating Doctors
10. Samplify Systems Announces Distribution Agreement With Tokyo Electron Device Limited, Broadening Availability of Signal Compression Technology
11. Pioneer(R) Surgical Technology Introduces the BacJac(TM) Interspinous Decompression System to the European Spine Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital ... a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood ... the Pepin Family Foundation. , “We greatly appreciate this gift from Constellation Brands. ...
(Date:2/19/2017)... , ... February 19, 2017 , ... ... for connected home healthcare, will join forces with Healthwise ® at ... Healthwise, the industry leader in evidence-based health education, technology and services, will ...
(Date:2/18/2017)... , ... February 17, 2017 , ... Park Cities Pet ... Behave” Show on the Pet Life Radio network. The episode, which was posted ... of topics including: what factors led to Park Cities Pet Sitter’s being awarded the ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... February 17, ... ... Devices, Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. ... , Do manufacturers distinguish between corrective action (CA) and preventive action ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... Feb. 19, 2017   AC Group Inc. , ... ranking of vendors in the PMS/EHR healthcare marketplace, will ... system requirements to succeed in this ecosystem at HIMSS,17. ... together information obtained from over 200 ACOs, compared and ... and services companies that are providing different pieces of ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
(Date:2/18/2017)... , Feb. 17, 2017  Pharmaceutical companies have long ... products either in development or already on the market.   ... the pharma industry to alter how it manages advisory board ... leader Best Practices, LLC conducted a new study focused on ... ...
Breaking Medicine Technology: